PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9418315-8	1997	The positive response to buspirone (5-HT1A) augmentation of fluvoxamine (SSRI) suggested that disturbed central serotonergic neurotransmission might play an important role in the pathogenesis of kleptomania.	Fluvoxamine	60-71	5-hydroxytryptamine receptor 1A	Homo sapiens	36-42	
15458611-3	2004	The aim of this study is to investigate a possible association between this 5-HT1A receptor variant and antidepressant response to fluvoxamine in a sample of 262 mood-disorder subjects (151 major depressed and 111 bipolars) treated with fluvoxamine for 6 wk.	Fluvoxamine	131-142	5-hydroxytryptamine receptor 1A	Homo sapiens	76-91	
15458611-3	2004	The aim of this study is to investigate a possible association between this 5-HT1A receptor variant and antidepressant response to fluvoxamine in a sample of 262 mood-disorder subjects (151 major depressed and 111 bipolars) treated with fluvoxamine for 6 wk.	Fluvoxamine	237-248	5-hydroxytryptamine receptor 1A	Homo sapiens	76-91	
15458611-6	2004	In bipolars, 5-HT1A*C/C genotype carriers showed a better response to fluvoxamine (p=0.036), independently from clinical variables.	Fluvoxamine	70-81	5-hydroxytryptamine receptor 1A	Homo sapiens	13-19	
15148501-1	2004	We investigated the effects of a 5-hydroxytryptamine (5-HT) 1A receptor gene polymorphism on the clinical response to fluvoxamine (FLV) in 65 depressed outpatients who gave written consent to participate in the study.	Fluvoxamine	118-129	5-hydroxytryptamine receptor 1A	Homo sapiens	33-71	
15148501-1	2004	We investigated the effects of a 5-hydroxytryptamine (5-HT) 1A receptor gene polymorphism on the clinical response to fluvoxamine (FLV) in 65 depressed outpatients who gave written consent to participate in the study.	Fluvoxamine	131-134	5-hydroxytryptamine receptor 1A	Homo sapiens	33-71	
8944409-10	1996	The blunting of GH and psychological responses suggest that 5-HT1A receptor function is reduced by chronic fluvoxamine treatment.	Fluvoxamine	107-118	5-hydroxytryptamine receptor 1A	Homo sapiens	60-75	
26712326-4	2016	The results confirmed that the selective 5-HT1A antagonist WAY-100635 (0.05 mg/kg) partially blocked the fluvoxamine-quetiapine synergistic effect (maximum DA increase dropped from 325% to 214%).	Fluvoxamine	105-116	5-hydroxytryptamine receptor 1A	Homo sapiens	41-47